New treatments for KRAS-mutant lung cancer
Direct Therapeutic Targeting of KRAS-Mutants in Lung Cancer
Developing approaches to treat people whose lung tumors carry KRAS mutations, including types beyond the G12C change.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11265092 on NIH RePORTER |
What this research studies
This project works to find ways to directly block KRAS mutations that drive many lung cancers. Scientists will combine biochemical and structural lab work with tests on tumor samples taken from patients and models grown from patient tumors. The team will look at how mutant KRAS switches between active and inactive states to reveal new drug targets and to understand how cancers adapt and become resistant. The goal is to guide development of therapies that help people with a wider range of KRAS-mutant lung cancers.
Who could benefit from this research
Good fit: People with lung cancer whose tumor testing shows a KRAS mutation (including non-G12C variants) would be the most relevant candidates.
Not a fit: People whose tumors do not have KRAS mutations are unlikely to benefit from the approaches in this project.
Why it matters
Potential benefit: If successful, this could expand effective drug options for people with KRAS-mutant lung cancer and help prevent or overcome treatment resistance.
How similar studies have performed: Recent drugs that target KRAS G12C have shown clinical benefit, but many other KRAS mutations and resistance mechanisms remain without effective targeted therapies.
Where this research is happening
New York, United States
- Sloan-Kettering Inst Can Research — New York, United States (Active)
Researchers
- Principal investigator: Lito, Piro — Sloan-Kettering Inst Can Research
- Study coordinator: Lito, Piro
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.